• Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum
  • New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes
  • Data from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvements
  • Case series highlights use of CRENESSITY in patients with classic CAH due to 11β‑hydroxylase deficiency
  • Additional ENDO 2026 presentations include VYKAT™ XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi syndrome (PWS), including late-breaking long-term extension findings following randomized withdrawal, and data evaluating sustained improvements in hyperphagia and behavioral symptoms through three years

SAN DIEGO, June 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to two years of treatment with CRENESSITY® (crinecerfont) in adult and pediatric populations with classic congenital adrenal hyperplasia. These data will be presented at the Endocrine Society's annual meeting, ENDO 2026, taking place from June 13-16, in Chicago.